業績報告 【publish】富永圭一 先生 Frontiers in Pharmacology誌

富永 圭一先生の論文が、Frontiers in Pharmacology誌(Journal Citation Reports Impact Factor 2019 = 4.225)にpublishされました。

Diagnostics 2020 Nov 10(12)
doi:10.3390/diagnostics10121007

Thiopurines: Recent Topics and Their Role in the Treatment of Inflammatory Bowel Diseases

Keiichi Tominaga, Takeshi Sugaya, Takanao Tanaka, Mimari Kanazawa, Makoto Iijima, Atsushi Irisawa

Affiliations expand
PMID: 33584261 PMCID: PMC7878672 DOI: 10.3389/fphar.2020.582291

Abstract
Ulcerative colitis (UC) and Crohn’s disease (CD) are chronic inflammatory bowel diseases (IBD) of unknown etiology, characterized by repeated relapse and remission. The efficacy of thiopurine in IBD was first reported in the late 1960s. Thiopurines are used to alleviate the symptoms of IBD, especially UC. These drugs have a steroid-sparing potential and are widely used for the purpose of maintaining long-term remission in steroid-dependent cases. Therefore, thiopurines tend to be used long-term, but adverse events that accompany long-term use, such as lymphoproliferative disorders, must be monitored with care. In contrast, thiopurine plays a critical role in controlling the immunogenicity of biologics. Furthermore, although thiopurine is an old drug, new findings, including the prediction of serious adverse events such as severe alopecia and acute advanced leukopenia, by nudix hydrolase 15 gene polymorphism analysis, as well as the possibility of appropriate drug monitoring by detailed analysis of 6-thioguanine nucleotides have been clarified. However, the consequences of thiopurine withdrawal have not been determined and further studies, including randomized controlled trials, are necessary to answer the clinical question regarding the scenarios in which thiopurine withdrawal is possible.

Keywords: biological agents; crohn’s disease; inflammatory bowel disease; pharmacological action; thiopurine; ulcerative colitis.